FilingReader Intelligence
Amoytop Biotech reports strong half-year growth in 2025
August 20, 2025 at 10:30 AM UTC•By FilingReader AI
Xiamen Amoytop Biotech Co reported revenue of 1.51 billion yuan for the first half of 2025, up 27% year-on-year. Net profit attributable to shareholders jumped 41% to 428 million yuan.
Operating cash flow surged 398% to 361 million yuan. Basic earnings per share grew 40% to 1.05 yuan, while return on net assets improved to 15.61%.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
SSE:688278•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Xiamen Amoytop Biotech publishes news
Free account required • Unsubscribe anytime